Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

LY3372993 in Healthy Participants and People with Alzheimer's

Start: November 5, 2018
End: May 2019
Enrollment: 100

What Is This Study About?

This Phase I study will test the safety and tolerability of the investigational drug LY3372993 in healthy adults and older adults with Alzheimer's disease. 

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: 85 Years

Must have:

Healthy Participants

  • Overtly healthy as determined by medical history and physical examination
  • Between 18 to 45 years old
  • Males must agree to use a reliable method of birth control during the study and 3 months following the last dose
  • Females not of childbearing potential
  • Body mass index of 18 to 32

Participants with Alzheimer's

  • Mild cognitive impairment due to Alzheimer's disease or or mild to moderate Alzheimer's
  • Positive florbetapir scan on positron emission tomography
  • Men or nonfertile women, at least 55 years of age
  • Have up to two study partners who can provide information about the participant

Must NOT have:

All Participants

  • Significant abnormalities on brain magnetic resonance imaging (MRI)
  • Inability to undergo MRI
  • Significant allergic reactions to LY3372993, or related compounds, or significant allergies to humanized monoclonal antibodies, diphenhydramine, epinephrine, or methylprednisolone
  • Clinically significant neurological or psychological illness, or other illnesses that could affect study results

Healthy Participants

  • Family history of early-onset Alzheimer's disease
  • Impaired cognitive function

Participants with Alzheimer's

  • History of intracranial hemorrhage, cerebrovascular aneurysm or arteriovenous malformation, carotid artery occlusion, or stroke or epilepsy
  • Previously dosed in any other study investigating active immunization against amyloid-beta
  • Previously dosed in any other study investigating passive immunization against amyloid-beta within the last 6 months
  • Current serious or unstable illnesses

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

Who Sponsors This Study?

Lead: Eli Lilly and Company

Source: ClinicalTrials.gov ID: NCT03720548

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health